Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Clinical Value Of Serum Tumor Markers In Assessing The Efficacy Of Neoadjuvant Chemotherapy In Advanced Ovarian Cancer: Single-center Prospective Clinical Study

Clinical value of serum tumor markers in assessing the efficacy of neoadjuvant chemotherapy in advanced ovarian cancer: single-center prospective clinical study

Jing Huang1, Danyi Du2, Hailong Chen1

  • 1Department of Gynecology and Oncology, Ganzhou Cancer Hospital, Ganzhou, Jiangxi, China.

Frontiers in Oncology
|June 12, 2024

Related Experiment Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.2K

View abstract on PubMed

Summary
This summary is machine-generated.

Biomarkers like Neutrophil-to-lymphocyte ratio (NLR) and CA199 show high predictive value for neoadjuvant chemotherapy (NACT) effectiveness in advanced ovarian cancer. Combining CA125 and HE4 offers a robust approach for patient selection and treatment planning.

Area of Science:

  • Oncology
  • Biochemistry
  • Clinical Diagnostics

Background:

  • Advanced ovarian cancer treatment relies on effective neoadjuvant chemotherapy (NACT).
  • Accurate prediction of NACT response is crucial for personalized treatment strategies.
  • Biomarker monitoring can offer insights into treatment efficacy.

Purpose of the Study:

  • To evaluate the clinical utility of biomarkers including Neutrophil-to-lymphocyte ratio (NLR), Carbohydrate Antigen (CEA), CA199, CA125, CA153, and Human Epididymis Protein 4 (HE4) in predicting NACT effectiveness for advanced ovarian cancer.
  • To assess the dynamic changes of these biomarkers during NACT.
  • To identify factors influencing NACT outcomes and optimize patient selection.

Main Methods:

  • Biomarker levels (NLR, CEA, CA199, CA125, CA153, HE4) were measured pre-chemotherapy and after three cycles.
Keywords:
efficacy of chemotherapyhuman epididymal protein 4neoadjuvant chemotherapyovarian cancer

Related Experiment Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.9K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.2K
  • Patients were stratified into effective and ineffective NACT groups.
  • Receiver operating characteristic (ROC) curves, predictive modeling, and multifactorial regression analysis were utilized to assess predictive values and influencing factors.

    • Main Results:

    • Higher pre-treatment age, maximum tumor diameter, CEA, and HE4 levels were observed in the effective NACT group (P <.05).
    • Significant differences in HE4 levels pre- and post-treatment were noted between effective and ineffective groups (P<.05).
    • NLR demonstrated 93.3% sensitivity and CA199 showed 92.3% specificity in predicting NACT effectiveness. HE4 had 75.3% sensitivity and 84.6% specificity. Combined CA125 and HE4 assays achieved an AUC of 0.825 for predicting NACT ineffectiveness.

    Conclusions:

    • NLR and CA199 exhibit strong predictive capabilities for NACT effectiveness in advanced ovarian cancer.
    • Combination assays of CA125 and HE4 provide enhanced predictive value for NACT response.
    • These biomarker assessments can aid in selecting suitable patients for NACT, timing interval debulking surgery, and achieving optimal tumor reduction.
    predictive indicators